These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1321541)

  • 1. [Hypereosinophilia syndrome. Apropos of 2 cases and literature review].
    Straetmans N; Ferrant A; Martiat P; Sokal G; Michaux JL
    Acta Clin Belg; 1992; 47(2):90-9. PubMed ID: 1321541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases].
    Coutant G; Blétry O; Prin L; Hauteville D; de Puyfontaine O; Abgrall JF; Godeau P
    Ann Med Interne (Paris); 1993; 144(4):243-50. PubMed ID: 8368716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy--case report and literature review.
    Baratta L; Afeltra A; Delfino M; De Castro S; Giorgino F; Rossi-Fanelli F
    Angiology; 2002; 53(4):465-70. PubMed ID: 12143954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration.
    Schöffski P; Ganser A; Pascheberg U; Büsche G; Gaede B; Hertenstein B
    Ann Hematol; 2000 Feb; 79(2):95-8. PubMed ID: 10741923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypereosinophilic syndrome in a myeloproliferative variety. Success after 18 month treatment with interferon alpha].
    Dine G; Najman A; Brahimi S; Culioli B; Abid A; Dupoirieux J
    Presse Med; 1992 Nov; 21(37):1776. PubMed ID: 1488427
    [No Abstract]   [Full Text] [Related]  

  • 9. Hypereosinophilic syndrome and plasmocytoma. Report of a case and review of the literature.
    Franchi F; De Rosa F; Seminara P; Calvieri S; Carfagna GF; Bosman C
    Acta Haematol; 1984; 72(1):14-20. PubMed ID: 6433626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interferon-alpha therapy in the myeloproliferative variants of hypereosinophilic syndrome].
    Kobayashi M; Katayama T; Ochiai S; Yoshida M; Kaito K; Masuoka H; Shimada T; Nishiwaki K; Sakai O
    Rinsho Ketsueki; 1993 Mar; 34(3):367-72. PubMed ID: 8479090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitral valve replacement in idiopathic hypereosinophilic syndrome.
    Blake DP; Palmer TE; Olinger GN
    J Thorac Cardiovasc Surg; 1985 Apr; 89(4):630-2. PubMed ID: 3982067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Idiopathic hypereosinophilic syndrome. Current clinico-therapeutic state].
    Mercadanti M; Cavalieri F; Ferraccioli GF; Ambanelli U
    Minerva Med; 1985 Oct; 76(39):1781-90. PubMed ID: 4047460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiopathic hypereosinophilic syndrome and "eosinophilic leukemia".
    Cassi E; De Paoli A; Fava S; Luoni M; Tosi A; Turri C; Grimi E
    Haematologica; 1992; 77(5):430-2. PubMed ID: 1483595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
    Borbényi Z
    Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eosinophilic myeloproliferative disorders.
    Klion AD
    Hematology Am Soc Hematol Educ Program; 2011; 2011():257-63. PubMed ID: 22160043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-Interferon treatment for idiopathic hypereosinophilic syndrome.
    Bockenstedt PL; Santinga JT; Bolling SF
    Am J Hematol; 1994 Mar; 45(3):248-51. PubMed ID: 8296798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endomyocardiopathy with eosinophilia.
    Solley GO; Maldonado JE; Gleich GJ; Giuliani ER; Hoagland HC; Pierre RV; Brown AL
    Mayo Clin Proc; 1976 Nov; 51(11):697-708. PubMed ID: 994551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy--a case report.
    Sakhuja V; Manjunath S; Varma S; Anand IS
    Indian Heart J; 1987; 39(1):82-4. PubMed ID: 3450575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.